Thursday 16 October, 2025
Introduction/Objectives: Tanezumab, a novel monoclonal antibody against nerve growth factor (NGF), is being developed to treat pain from moderate-to-severe osteoarthritis…
Read morePoster: Drug/Disease Modelling - CNS
A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia
Thursday 16 October, 2025
Objectives: This analysis aimed to develop a Model Based Meta-Analysis (MBMA)comparator model to provide a quantitative framework for the comparison…
Read morePopulation pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data
Thursday 16 October, 2025
Introduction: Premature infants have a high risk of developing neonatal seizures [1]. Levetiracetam is a second-generation broad spectrum antiepileptic drug…
Read moreDose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity
Thursday 16 October, 2025
Objectives: Several risperidone and paliperidone oral and long-acting injectable (LAI) formulations, each characterized by a unique pharmacokinetic (PK) profile, are available…
Read morePharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis
Thursday 16 October, 2025
Objectives: Children with severe acute bronchiolitis often require mechanical ventilation with sedation to decrease anxiety and discomfort of the intubation. Opioid…
Read moreA quantitative framework integrating exposure, efficacy, receptor occupancy and tolerability to propose evidence-based dose regimens for padsevonil
Thursday 16 October, 2025
Objectives: To develop a quantitative framework integrating pharmacokinetics (PK), receptor occupancy (RO), clinical outcome (PKPD) and tolerability data at the…
Read morePopulation PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease
Thursday 16 October, 2025
Objectives: RO7046015 (also known as PRX002 or RG7935), a monoclonal antibody (Ab) targeting alpha-synuclein (aSyn), is currently in development for…
Read moreModeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment.
Thursday 16 October, 2025
Objectives: The main pathophysiological hypothesis for the development of Alzheimer’s disease currently identifies two abnormal structures suspected to damage neurons…
Read morePhase III dose selection for evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: exposure-response analyses from a phase II study in patients with multiple sclerosis
Thursday 16 October, 2025
Introduction: Evobrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor currently in development for the treatment of multiple sclerosis…
Read morePopulation pharmacokinetic – pharmacodynamic analysis of dopamine D2 receptor occupancy following doses of TV 46000, an extended release suspension of risperidone for treatment of schizophrenia
Thursday 16 October, 2025
Background: TV‑46000 is a long-acting subcutaneous risperidone injection with flexible dosing either once monthly (q1m) or once every two months…
Read more